{"id":579206,"date":"2026-04-28T07:00:53","date_gmt":"2026-04-28T07:00:53","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/?p=579206"},"modified":"2026-04-28T07:01:42","modified_gmt":"2026-04-28T07:01:42","slug":"5-medtech-trends-to-watch-in-2026","status":"publish","type":"post","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/blog\/5-medtech-trends-to-watch-in-2026\/","title":{"rendered":"5 medtech trends to watch in 2026"},"content":{"rendered":"

The medtech landscape is entering a period of accelerated change. Structural forces across global pricing, care delivery, supply chains, clinical pathways, and enabling technologies are shaping how companies compete and where growth will occur. While our Medtech Trends to Watch 2026<\/a> e\u2011book explores these dynamics in depth through proprietary data and expert analysis, this blog highlights several of the important medtech market trends and why they matter.<\/p>\n

1. Mainland China\u2019s VBP expansion is redefining global market economics<\/h3>\n

Mainland China\u2019s latest national volume\u2011based procurement (VBP) round marks one of the most consequential shifts in global medtech pricing<\/a>. Originally intended to expand patient access and curb high device costs, the program has evolved into a powerful market\u2011structuring mechanism. The newest rules introduce more sophisticated anchor\u2011price logic, deeper price compression, and allocation systems that support domestic manufacturers.<\/p>\n

For multinational companies, VBP is no longer a localized policy, and it is influencing expectations around price, volume, and competitive positioning in markets well beyond Mainland China.<\/p>\n

Why it matters:<\/strong> VBP is accelerating domestic innovation, reshaping portfolio strategy, and redefining how companies must think about participating in one of the world\u2019s largest medtech markets. Read more about it\u2019s pricing dynamics, competitive shifts, and strategic implications<\/a>.<\/p>\n

2. Outpatient and ASC settings are becoming central to procedure strategy<\/h3>\n

The continued migration of procedures from hospitals to outpatient settings remains one of the most important medtech trends. The U.S. Centers for Medicare & Medicaid Services (CMS)\u2019 2026 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System Final Rule reinforces this trend, expanding the ASC Covered Procedure List and phasing out the inpatient\u2011only list. These changes open the door for higher\u2011acuity procedures, such as cardiac ablation, to move into lower\u2011cost settings when clinically appropriate.<\/p>\n

This shift builds on long\u2011running patterns in orthopedics, general surgery, and other specialties, where ASCs have become critical to growth strategies for both providers and manufacturers.<\/p>\n

Why it matters:<\/strong> As more procedures become ASC\u2011eligible, medtech companies must adapt their commercial models, economic value propositions, and product designs to meet the needs of diverse sites of service. Read more about how this is set to reshape procedure dynamics across therapy areas<\/a>.<\/p>\n

3. Global trade and supply chain pressures are reshaping manufacturing strategy<\/h3>\n

Supply chain resilience is becoming a strategic imperative and one of the defining medtech industry trends. Tariff exposure, geopolitical factors, and fluctuating material costs are challenging long\u2011standing assumptions about where and how devices should be produced. These pressures are prompting companies to diversify sourcing, re-evaluate business strategies, and pursue more flexible multi\u2011region manufacturing footprints \u2013 clear indicators of evolving medtech market trends.<\/p>\n

Larger manufacturers are also using scale, integration, and technology investment to buffer against global volatility, trends that could further reshape competitive dynamics across categories.<\/p>\n

Why it matters:<\/strong> Cost structures, supplier concentration, manufacturing geography, and product portfolio rebalancing will increasingly influence competitive advantage, not just product performance. Read more about tariff dynamics, key materials in device manufacturing, supply chain instability and what companies are doing to better position themselves for ongoing variability in the global environment<\/a>.<\/p>\n

4. GLP\u20111 therapies are shifting patient behavior and reshaping care pathways<\/h3>\n

The rapid adoption of glucagon-like peptide-1 (GLP-1) receptor agonists is altering how patients and clinicians approach weight management and related comorbidities. While bariatric surgery remains the most effective intervention for substantial weight loss, GLP\u20111s have rapidly expanded in popularity, changing referral patterns and influencing demand across adjacent Medtech categories.<\/p>\n

Their impact is not uniform. Certain bariatric procedures are experiencing sharper volume pressure than others, and downstream effects\u2014ranging from diabetes care to sleep apnea to cardiovascular monitoring\u2014are only beginning to emerge.<\/p>\n

Why it matters:<\/strong> The GLP\u20111 effect reflects a broader shift in how metabolic disease is managed, with ripple effects across multiple device markets and clinical pathways. Read more about the impact on specific procedure types, how clinical practices is shifting, as well as the market outlook and cross-sector implications<\/a>.<\/p>\n

5. Enabling technologies are driving the shift toward platform\u2011based competition<\/h3>\n

Across Medtech, enabling technologies including robotics, imaging, navigation, and digital workflow software are reshaping how companies differentiate and compete. These technologies are no longer adjuncts to procedures; they are becoming central to integrated ecosystems that support clinical planning, surgical execution, and postoperative care.<\/p>\n

Companies are investing heavily in platform architectures that can anchor entire service lines, strengthen customer relationships, and unlock new data\u2011driven value propositions. Emerging open\u2011platform systems are also expanding flexibility and creating new competitive dynamics.<\/p>\n

Why it matters:<\/strong> Platform\u2011based competition is redefining how companies deliver value, engage customers, and create long\u2011term strategic advantage. Read more about robotics, integration of imaging, navigation, and intraoperative intelligence, and end-to-end digital workflows<\/a>.<\/p>\n

Looking ahead<\/h3>\n

Across markets, care settings, and technology categories, the forces shaping today\u2019s medtech trend are creating both pressure and possibility. These trends highlighted here illustrate just how quickly the landscape is evolving for manufacturers, providers, and policymakers.<\/p>\n

While each trend follows its own trajectory, together they point to broader structural shifts that are redefining competitive strategy, customer engagement, and expectations around value. Understanding how these forces interact will be essential for navigating near\u2011term uncertainty while making informed decisions that shape the long term.<\/p>\n

The organizations best positioned for the future will be those that can translate these shifts into thoughtful strategy, smarter investment, and stronger partnerships across the medtech ecosystem.<\/p>\n

Download the full Medtech Trends to Watch 2026 e-book to explore these themes and underlying data in greater depth<\/strong><\/a>.<\/p>\n

Medtech Trends to Watch 2026 offers a more detailed view of the market dynamics and strategic considerations that will shape the medtech<\/a> industry\u2019s next chapter.<\/p>\n","protected":false},"excerpt":{"rendered":"

The medtech landscape is entering a period of accelerated change. Structural forces across global pricing, care delivery, supply chains, clinical pathways, and enabling technologies are shaping how companies compete and…<\/p>\n","protected":false},"author":313,"featured_media":579603,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_links_to":"","_links_to_type":0,"footnotes":""},"categories":[23],"tags":[118,1623,133,2831,2833],"class_list":["post-579206","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medtech","tag-digital-health","tag-glp-1","tag-medtech","tag-supply-chain","tag-china"],"acf":[],"lang":"en","translations":{"en":579206,"ja":580187,"ko":580188},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/579206","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/users\/313"}],"replies":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/comments?post=579206"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/579206\/revisions"}],"predecessor-version":[{"id":579208,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/posts\/579206\/revisions\/579208"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media\/579603"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=579206"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/categories?post=579206"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/tags?post=579206"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}